HOME arrow News & PR

News & PR

News & PR
No Subject Date
19 RegeneRx Update on Dry Eye and EB Clinical Trials 2019.01.04
18 RegeneRx Partner Updates on Clinical Trials 2018.10.29
17 World Health Organization Recommends INN for Thymosin Beta 4 as "timbetasin" 2018.09.06
16 RGN-259 (Tβ4) Improves Clinically Important Dry Eye Efficacies in Comparison with Prescription Drugs in Dry Ey... 2018.07.16
15 ReGenTree Announces the Results of the ARISE-2 Trial With RGN-259 for the Treatment of Dry Eye: Significant Ef... 2017.10.31
14 RegeneRx JV Presents Results of Phase 2b/3 (ARISE-1) Dry Eye Trial at ARVO 2017 2017.05.09
13 RegeneRx Announces First Patients Enrolled in Phase 3 U.S. Dry Eye Clinical Trial (ARISE-2 Trial) with RGN-259... 2016.11.09
12 RGN-259 Confirms Efficacy in Signs and Symptoms of Dry Eye 2016.05.06
11 RegeneRx and ReGenTree Expand License for Dry Eye 2016.04.28
10 RegeneRx Announces Completion of Patient Enrollment In Phase 2b/3 U.S. Dry Eye Trial 2016.01.29
9 RegeneRx U.S. Joint Venture, ReGenTree, Launches Web Site 2016.01.28
8 RegeneRx Updates on U.S. Ophthalmic Clinical Trials 2015.10.21
7 RegeneRx Announces First Patient Enrolled in Phase 3 U.S. Neurotrophic Keratopathy (NK) Clinical Trial with RG... 2015.09.21
6 RegeneRx Announces First Patients Enrolled in Phase 2b/3 U.S. Dry Eye Clinical Trial with RGN-259 2015.09.16
5 RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S... 2015.04.16
4 RegeneRx Joint Venture Partner Receives $7.28 million USD From Korean Government and Venture Fund for U.S. Dev... 2015.03.09
3 RegeneRx and G-treeBNT Create Joint Venture to Develop RGN-259 in the U.S. 2015.01.28
처음페이지이전 10 페이지1다음 10 페이지마지막페이지